Amlodipine/atorvastatin (Caduet) for preventing heart disease

American Family Physician

Volumn 73, Issue 6, 2006, Pages 1067-1069

  Wilson, Stephen A ^a   Sanford, Annette ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN;

ABDOMINAL PAIN; ANGINA PECTORIS; CLINICAL TRIAL; CONSTIPATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; ERYTHEMA MULTIFORME; FLATULENCE; HEADACHE; HEART DISEASE; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIVER TOXICITY; RHABDOMYOLYSIS; SHORT SURVEY; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

AMLODIPINE; DRUG COMBINATIONS; HEART DISEASES; HEPTANOIC ACIDS; HUMANS; PYRROLES; TREATMENT OUTCOME;

EID: 33645007118     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Caduet (amlodipine/atorvastatin) tablets. Product information. New York: Pfizer Labs, 2004. Accessed online November 29, 2005, at: http://www.pfizer.com/ pfizer/download/uspi_caduet.pdf.
2. Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens 2005;7:264-73.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
4. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31.
5. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-25.
6. Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy [published correction appears in J Am Coll Cardiol 2002;39:1409-10]. J Am Coll Cardiol 2002;39:315-22.
7. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
8. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;364:685-96.
9. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8.